Table 2.
Patient | Valproate dosage (mg/kg/day) | Day 0 | Day 3 | |||
---|---|---|---|---|---|---|
MFI | Bound CD20 mAbs per cell | MFI | Bound CD20 mAbs per cell | Plasma valproate (μM) | ||
003 | 30 | 2163 | 6866 | 7602 | 18035 | *407 |
008 | 80 | 30893 | 70229 | 34322 | 78890 | 656 |
010 | 80 | 35540 | 69096 | 41605 | 79260 | 847 |
An FNB of an affected lymph node was performed before treatment start as well as morning day 3, cycle 1 in patients 003, 008 and 010 of the VALFRID study. Lymphoma cells (i.e., monoclonal B-cells) were analysed by FACS as described in materials and methods, and the number of bound CD20 antibodies to the cell surface was calculated by normalisation by the QuantiBRITE assay using geometric mean fluorescence intensity (MFI). Corresponding doses and serum levels of valproate are indicated (*: Day 2).